Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States.
+ 2 more risks
Slightly overvalued with limited growth.
Share Price & News
How has Iterum Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ITRM's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ITRM underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.
Return vs Market: ITRM underperformed the US Market which returned 18.7% over the past year.
Price Volatility Vs. Market
How volatile is Iterum Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StHow Iterum Therapeutics plc (NASDAQ:ITRM) Can Impact Your Portfolio Volatility
7 months ago | Simply Wall StThe Iterum Therapeutics (NASDAQ:ITRM) Share Price Is Down 22% So Some Shareholders Are Getting Worried
9 months ago | Simply Wall StWhat Kind Of Investor Owns Most Of Iterum Therapeutics plc (NASDAQ:ITRM)?
Is Iterum Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ITRM ($0.91) is trading below our estimate of fair value ($11.8)
Significantly Below Fair Value: ITRM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ITRM is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ITRM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ITRM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ITRM has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.
How is Iterum Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ITRM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ITRM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ITRM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ITRM's revenue (77.1% per year) is forecast to grow faster than the US market (9.5% per year).
High Growth Revenue: ITRM's revenue (77.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ITRM's Return on Equity is forecast to be high in 3 years time
How has Iterum Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ITRM is currently unprofitable.
Growing Profit Margin: ITRM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ITRM is unprofitable, and losses have increased over the past 5 years at a rate of 40.8% per year.
Accelerating Growth: Unable to compare ITRM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ITRM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.1%).
Return on Equity
High ROE: ITRM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Iterum Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ITRM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ITRM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ITRM has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ITRM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ITRM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ITRM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 38.6% each year
What is Iterum Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ITRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ITRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ITRM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ITRM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ITRM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Corey Fishman (55 yo)
Mr. Corey N. Fishman serves as Independent Director at BioSpecifics Technologies Corp. since April 9, 2020. Mr. Fishman has been the Chief Executive Officer of Iterum Therapeutics Ltd since November 2015 a ...
CEO Compensation Analysis
Compensation vs Market: Corey's total compensation ($USD1.39M) is above average for companies of similar size in the US market ($USD589.02K).
Compensation vs Earnings: Corey's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||4.75yrs||US$565.09k||0.26% |
|Chief Scientific Officer||4.75yrs||US$883.11k||0.70% |
|Vice President of Operations||5.58yrs||no data||no data|
|VP & CMC Head||no data||no data||no data|
|Secretary||no data||no data||no data|
Experienced Management: ITRM's management team is considered experienced (4.8 years average tenure).
|Independent Interim Chairman||1.17yrs||US$122.50k||0.029% |
|Independent Director||4.75yrs||US$119.00k||0.042% |
|Independent Director||4.75yrs||US$131.00k||0.027% |
|Independent Director||3.25yrs||US$125.00k||0.053% |
|Independent Director||4yrs||US$139.00k||0.17% |
|Independent Director||3.25yrs||US$128.50k||0.056% |
Experienced Board: ITRM's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 47.8%.
Iterum Therapeutics plc's company bio, employee growth, exchange listings and data sources
- Name: Iterum Therapeutics plc
- Ticker: ITRM
- Exchange: NasdaqGM
- Founded: 2015
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$18.903m
- Shares outstanding: 21.24m
- Website: https://www.iterumtx.com
Number of Employees
- Iterum Therapeutics plc
- Harcourt Centre
- Block 2, Floor 3
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ITRM||NasdaqGM (Nasdaq Global Market)||Yes||Ordinary Shares||US||USD||May 2018|
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulope ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/14 13:05|
|End of Day Share Price||2020/08/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.